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Available online 11 May 2019Aim. In countries likeDenmark, cervical cancer incidence is at present relatively high in elderlywomen, while
routine screening stops at age 65 years. On this background, all women aged69 and abovewere invited to human
papillomavirus (HPV)-screening in Denmark in 2017.
Methods.Womenwere identified from the Central Population Register and personally invited by digital or or-
dinary mail to have a screening sample taken by their general practitioner. In four regions, samples were tested
for high risk (HPV) with the cobas 4800® HPV-assay, and in the last region with the BD Onclarity® HPV-assay.
Participation rate, prevalence of high risk HPV, and proportion of positive samples with HPV16, HPV18, and
other high risk HPV-types were tabulated by 5-year age-groups.
Results. 455,612 women were invited, and 30.2% (95 confidence interval (CI) 30.0–30.3) participated. Aver-
age age of participants was 74.6 years. Overall, 4.3% (95% CI 4.1–4.4) of participants were HPV-positive, of
whom 24% had HPV 16/18. HPV-prevalence decreased slightly from 4.5% in women aged 69–73 years to 3.1%
in women aged 84–88 years, but was 5.2% in the very small group of participants aged 89+ years.
Conclusion. Invitation to HPV-screening waswell received by elderly women. The HPV-prevalence decreased
slightly with increasing age. No rebound of HPV-prevalence after menopause was found when our data were
combined with previously published Danish data from younger women. The presently relatively high cervical
cancer incidence in elderly women was not reflected in the HPV-prevalence.
© 2019 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).Keywords:
Cervical cancer
Screening
Human papillomavirus
Age
Prevalenceetermined significance; CI, Confidence interval; HPV, Human Papillomavirus.
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119B. Andersen et al. / Gynecologic Oncology 154 (2019) 118–1231. IntroductionInmany high-income countries the age-specific incidence of cervical
cancer at present shows a bipolar pattern with a first top on the inci-
dence curve around the age of 35–40 years, and a second top around
the age of 65–80 years. The first top on the incidence curve is well ex-
plained by the biology of cervical cancer and the unset of sexual life,
as a persistent infection with high-risk human papillomavirus (HPV)
is a precondition for development of this cancer; HPV-infection is sexu-
ally transmitted; and there is a long latency period from first persistent
infection to cancer development. The second top on the incidence curve
has beenmore difficult to explain. This top has been hypothesized to be
associated with mid-life change of sexual partners or with reactivation
of a latent HPV-infection as the immune system degenerates with age
[1]. It should, however, be taken into account that after 50 years of
screening, the current age-specific incidence of cervical cancer is no lon-
ger a pure reflection of the underlying risk of the disease, but it reflects
also the screening history of the respective birth cohort. A study of cer-
vical cancer patients aged 60 and above in Denmark in 2009–2013
found the average age of non-screened patients to be 76 years, in line
with the current second top on the incidence curve [2].
In Denmark, cervical screening started on a county-basis between
the late 1960's and the late 1990's. Since 2012, screening has been of-
fered every third year to women aged 23–49 years, and every fifth
year to women aged 50–65 years [3]. In 2015, the bipolar pattern in
the age-specific incidence of cervical cancer became an issue of concern
with theDaneAge Association and theDanish Cancer Society arguing for
extension of the upper limit of screening age. This led to an analysis of
the age-specific incidence of cervical cancer by birth cohort [4]. The
analysis showed that the incidence pattern within a given birth cohort
was unipolar at a gradually lower level for successively younger birth
cohorts indicating that the current incidence peak in elderly women
was a residual derived from previous, incomplete screening of these
birth cohorts.
On this basis, the upcoming generations were expected to have a
lower cervical cancer incidence in old age than seen today, and a perma-
nent extension of the upper limit of the screening age might therefore
not to be needed. There was, however, good evidence for offering
screening once to the previously under-screened elderly women. Con-
sequently, in 2017 Danish women born before 1948 were all personally
invited to HPV-testing. In the present paper we report on the outcome
of this screening.Table 1
Organisation of cervical screening for elderly women in Denmark by region.
Activity Regiona
North Central South
Data retrieval for
population
15 March 2017 15 March 2017 15 Marc
Invitation period 2 June – 14 Nov 2017 20 April – 27 Sept 2017 2 May –
Invitation order Youngest first By birth day By birth
Invitation method Digitalb Digitalb Digitalb
End of HPV-testing 17 May 2018 1 Jan 2018 Vejle: co
Esbjerg/
2018
HPV-assay Cobas 4800© Cobas 4800© Cobas 48
Result reported 16, 18, otherc, negative 16, 18, otherc, negative 16. 18, o
Cytology triage Other only Other only All posit
Referral for colposcopy 16, 18, other with ASCUS
+d
16, 18, other with ASCUS
+d
18, 18, o
Notes.
a Full names of regions: The North Denmark Region, The Central Denmark Region, The Regi
b Women exempted from digital communication were invited by ordinary mail.
c Other high risk HPV-types than 16 and 18.
d Atypical squamous cells of undetermined significance and worse.2. Material and methods
2.1. Regional organisation of intervention
The special offer of screening for elderly women was part of Cancer
Plan IV implemented by the Danish Government, the Danish Regions,
and the Danish Municipalities in 2017. All women born before 1948
should be invited to screening in 2017, and according to the cancer
plan primary HPV-testing should be used as the screening test.
Women with a positive test should be followed up in the same way as
test-positive women aged 60–64 years [5].
Screening in Denmark is organised by the five regions following na-
tional guidelines. Accordingly, the screening of elderly women was
organised in part similarly and in part with differences across regions.
A common invitation letter was developed by the National Health Au-
thority. As in the screening programme, women were invited to make
an appointment with their general practitioner to have the sample
taken. Reminders were not used. All regions informed the general prac-
titioners before the screening activity started, and the outcome of
screening for the individual woman was reported back to her general
practitioner,whowas responsible for the follow-up in case of abnormal-
ity. Screening and eventual follow-up were free of charge for the
woman.
Differences across regions were found in dates for retrieval of
data for target population; in length of calendar periods used for in-
vitation; in order of invitations by women's age; in invitation
method; in length of period within which HPV-testing was used;
in HPV-assay used; in use of cytology triage; and in rules applied
for referral for colposcopy (Table 1). In general, the screening activ-
ity was organised fairly similarly in the North, Central, South and
Zealand regions, while the Capital region followed slightly different
procedures. The main differences being that the first four regions
used digital invitations to the women's secured e-mail addresses,
while the Capital region used ordinary mail. Furthermore, the
North, Central, South and Zealand regions used the Cobas 4800®
HPV-assay from Roche, while the Capital region used the BD
Onclarity® HPV-assay. In the four regions, women with HPV 16 or
18, and women with other high risk types of HPV and abnormal cy-
tology were referred for colposcopy, while women with other high
risk HPV types than 16 and 18 and normal cytology were invited to
repeated HPV test in a year. In the Capital region, all high risk HPV-
positive women were referred for colposcopy.Zealand Capital
h 2017 15 March 2017 Before invitation of given birth
cohort
31 Oct 2017 2 May – 31 Dec 2017 8 May 2017–22 June 2017
10 August 2017–16 October 2017
day Youngest + oldest first Youngest first
Digitalb Ordinary mail
ntinued
Sønderborg: 31 May
1 July 2018 1 Oct 2018
00© Cobas 4800© BD Onclarity©
therc, negative 16, 18, otherc, negative 16, 18, otherc negative
ive Other only None
ther with ASCUS+d 16, 18, other with ASCUS
+d
All HPV-positive
on of Southern Denmark, Region Zealand, The Capital Region of Denmark.
Fig. 1. Flow diagram for analysis of cervical screening for women born before 1948 in
Denmark in 2017.
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For the analysis, datawere retrieved from theCentral PopulationReg-
ister on women born in 1947 or earlier and living in Denmark on 15
March 2017, and on dates of death and emigration in these women dur-
ing the period 15March 2017 to 31 June 2018. Data on cytology samples
taken in the invited women between 15 March 2017 and 31 June 2018
were retrieved from the National Pathology Register. In addition, in
women with a sample, data were retrieved on previous samples within
the last year. Data on hysterectomies in womenwithout a cytology sam-
plewere retrieved from the National Patient Register from 1977 to 2017.
The HPV-testswere coded for adequacy and outcome of HPV-test into
four categories HPV-16; HPV18; other HPV-types; and HPV-negative. The
outcomes of cytology triage and follow-up testing are not included in the
present report. Definitions and codes are listed in Supplementary Table 1.2.3. Analysis
As individual dates of invitationwere not known, allwomenwithout
a sample who died or emigrated between 15 March 2017 and 31 JuneTable 2
Number of invited women, women with follow-up test, participating women, ineligible wome
Invited
women
Sample taken Sample not take
Age in
yearsa
Birth
cohorta
In
follow-up
Participants Dead/emigrated
69–73 1943–47 170,073 2257 60,921 3451
74–78 1938–42 116,067 926 31,990 4088
79–83 1933–37 80,524 262 12,057 5342
84–88 1928–32 50,955 60 3122 6206
89+ 1909–27 37,993 12 495 9441
Total 455,612 3517 108,585 28,582
Notes.
a 69–73 years defined as women born 1943–1947. Approximate age, as almost one fourth of
for the other age-groups.
b Invited women− (in follow-up + dead/emigrated + hysterectomized).2018 were considered ineligible for screening. Participation rate was
calculated as [women with a sample/(invited women − (women in
follow-up + dead/emigrated women + hysterectomised women))].
Percent HPV-positive women was calculated as (women HPV-
positive/women with sample adequate for HPV-testing). 95% confi-
dence intervals (CI) were calculated with the Clopper-Pearson method.
For the present analysis data were retrieved centrally by the Danish
Clinical Registries. Data were analysed using SAS version 9.4. The study
was part of the routine quality assurance of cervical screening in
Denmark. The Central Denmark Region guaranteed that data were
used in accordance with the data protection legislation.
3. Results
In total, 455,612 women were invited, ranging from 36,133 women
born in 1947 to 9 women born in 1909 or earlier. Out of these women
112,102 had at least one sample taken between 15 March 2017 and
31 June 2018. For 3517 women, their sample seemed to be a follow-
up of earlier findings, as they had a previous sample taken less than
one year before. As a result, 108,585 women participated in the screen-
ing. The mean age of participants was 74.6 years.
Of those without a sample, 28,528 died or emigrated between 15
March 2017 and 31 June 2018. Furthermore, 63,804 women without a
sample were hysterectomized before 15 March 2017. Women in
follow-up, dead/emigrated, or hysterectomized were considered ineli-
gible for screening. As a result, 251,178 eligible women did not partici-
pate in the screening (Fig. 1). In total, 30.2% of eligible women
participated in the screening, ranging from 44.0% in women aged
69–73 years to 1.9% among women aged 89+ years (Table 2).
Overall, 4.1% of participating women were HPV-positive. Among
women in follow-up this percentage was 10.4% (Table 3). Together,
4.3% (95%CI 4.1–4.4) of all screenedwomenwere HPV-positive; slightly
decreasing from 4.5% (95% CI 4.4–4.7) in women aged 69–73 years, to
3.1% (95% CI 2.5–3.7) in women aged 84–88 years; and being 5.2%
(95% CI 3.4–7.5) in women aged 89+ years based on the very small
numbers. Among HPV-positive women, HPV16 was found in 20%;
HPV18 in 5%; other HPV-types in 81%; and HPV16/18 in 24% (Table 4).
These numbers add up to more than 100%, as a given woman can
have more than one infection type. Among HPV-positive women,
there was a slight increase in proportion of HPV16/18 positive from
24% in women aged 69–73 years, to 33% in women aged 84–88 years.
4. Discussion
4.1. Main result
The offer of cervical screening to elderly women was well received
with 44% of women in their early 70s participating; 35% of women in
their late 70s; and close to 20% of women in their early 80s. This was
less than the overall 67% of women responding to invitation withinn due to death/emigration, ineligible women due to hysterectomy.
n Eligible
womenb
Percent
participants/eligible
95% confidence
interval
Hysterect-omised
25,865 138,500 44.0% 43.7–44.3
18,225 92,828 34.5% 34.2–34.8
11,383 63,537 19.0% 18.7–19.3
5697 38,992 8.0% 7.7–8.3
2634 25,906 1.9% 1.7–2.1
63,804 359,763 30.2% 30.0–30.3
women born in 1947 will have turned 70 years on 15March 2017. Same principle applied
Table 3
Number of participants with adequate HPV-test, with positive HPV-test, and by HPV-type.
Participants Women in follow-up Total percent
positive
HPV-test
95%
confidence
interval
Age in
yearsa
All Adequate
HPV-test
Positive
HPV-test
Percent
positive
95%
confidence
interval
All Adequate
HPV-test
Positive
HPV-test
Percent
positive
69–73 60,921 60,861 2621 4.3% 4.1–4.5 2257 2112 234 11.1% 4.5% 4.4–4.7
74–78 31,990 31,963 1322 4.1% 3.9–4.4 926 864 78 9.0% 4.3% 4.0–4.5
79–83 12,057 12,038 420 3.5% 3.2–3.8 262 239 21 8.8% 3.6% 3.3–3.9
84–88 3122 3116 91 2.9% 2.4–3.6 60 54 6 11.1% 3.1% 2.5–3.7
89+ 495 492 25 5.1% 3.3–7.4 12 10 1 10.0% 5.2% 3.4–7.5
Total 108,585 108,470 4479 4.1% 4.0–4.2 3517 3279 340 10.4% 4.3% 4.1–4.4
Notes.
a See definition Table 2.
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count that almost half of women responding in the regular screening
programme come after at least one of the two reminders, while no re-
minder was used in this special offer to elderly women.
In total, 4% of elderly women were HPV-positive, a proportion
slightly decreasing across age-groups, and among the HPV-positive
women 24% had HPV16/18.
4.2. Other studies
In the Central region, a number of women previously, erroneously
exempted from invitation to screening were invited in 2013. At time
of invitation, the group included 5976 women aged 70 years and
above, of whom 8.1% were HPV-tested, and 4.9% (95% CI 3.2–7.2) of
the tested women were HPV-positive [7]. This was well in line with
the 4.3% (95% CI 4.1–4.4) found in this study of elderly women. The
2013-group was tested with the Cobas 4800 assay, which was also the
predominant assay used in this study of elderly women. As only 8.1%
of the target group were HPV-tested in the 2013-group as compared
with 24.5% in the present study, the concordance between the HPV-
positivity rates indicated that these rates seem to be robust to a poten-
tial selection bias.
Consecutive liquid-based cytology samples from 40,382women col-
lected in 2002–2005 from the pathology department in the Capital re-
gion were analysed with the Hybrid Capture 2® HPV-assay [8]. The
HPV-positivity rates varied from 46% for women aged 20–23 years, de-
creased rapidly after the age of 35, and reached 5.7% (95% CI 4.4–7.3) for
women aged 65+ years. Although this was an open age-group, the
HPV-positivity rate here was well in accordance with an HPV-
positivity rate of 6.0% (95% CI 4.2–8.2) found for 65–69 years old
women in the 2013-study [7]. While the HPV-positivity rate thus de-
clined rapidly after 35 years of age, a slowly declining rate was seen
throughout the rest of the women's lives (Fig. 2).
As part of the National Social Life Health and Aging Project in the
United States in 2005–2006, self-administered vaginal swab specimens
were collected from 1010 women and tested with Hybrid Capture 2®.
Mean age was 68 years, and 6% (95% CI 4.5–7.9) were HPV-positiveTable 4
Number of women with positive HPV-test by subtype.
Age in yearsa Positive HPV HPV-positive
typed
HPV 16 HP
Numberb % of positive with type Nu
69–73 2621 2611 499 19% 1
74–78 1322 1319 256 19%
79–83 420 420 86 20%
84–88 91 91 25 27%
89+ 25 25 8 32%
Total 4479 4466 874 20% 2
Notes.
a See definition Table 2.
b Numbers not mutually exclusive.[9]. In a gynecology outpatient clinic in Sweden in 2013–2015,
clinician-collected samples from 1051 women were tested with a mul-
tiplex real-time PCR-assay. Mean age was 68 years, and 4.1% (95% CI
3.0–5.5) were HPV-positive [10]. These results are in line with the Dan-
ish data.
4.3. Strengths and limitations
The number of invited women was 455,612, which was well in ac-
cordance with the number of 462,765 women aged 69 years and
above in Denmark on 1 April 2017 [11], as almost one fourth of the
women born in 1947 had turned 70 years before 15 March 2017. The
Danish Patient Register became nationwide in 1978. As hysterectomy
is a rare event before the age of 40 [12],we can assume to know thehys-
terectomy history for women born in 1938 or later, while the true hys-
terectomy rate for women born before 1938 is likely to be higher than
recorded here.
We cannot rule out selection in participation. It was, however, note-
worthy that the HPV-positivity rates for women aged 70 years and
above corresponded well between our study where 25% of women par-
ticipated and the 2013-study where only 8% participated. When we
compare with other studies, we cannot rule out differences in results
deriving from differences between HPV-assays. In the present study
the majority of samples were tested by Cobas 4800 and a minority
with BD Onclarity. In the Capital region data for women below age 70
(Fig. 2), Hybrid Capture 2® was used for the testing. However, in a
split-sample study of 5072 consecutive liquid-based cytology samples
from the Capital region collected in 2011, overall 20.4% tested positive
on Hybrid Capture 2®, while 26.8% tested positive on Cobas 4800 [13],
so if anything, the rates for elderly women are overestimated in this
comparison.
4.4. Interpretation
To our knowledge this is the first population-based HPV-screening
study offered to all women above the age of 69 years. We compared
the HPV-prevalence in these elderly women with those available fromV 18 HPV other HPV 16/18
mberb % of positive with type Numberb % of positive with type % of positive
with type
23 5% 2140 82% 24%
56 4% 1075 82% 23%
19 5% 331 79% 25%
5 5% 66 73% 33%
1 4% 19 76% 36%
04 5% 3631 81% 24%
Fig. 2. Prevalence of high risk HPV-positivity in Danish women, aged 20–65 from 2002 to 2005 and aged 69+ from 2017, observed and adjusted1 cervical cancer incidence 2011–2015.
122 B. Andersen et al. / Gynecologic Oncology 154 (2019) 118–123younger age-groups of Danish women. After the age of 35 years, the
HPV-prevalence decreased gradually with increasing age.
HPV-prevalence data from Northern Europe covering ages up to 65
+ years have indicated a moderate rebound after menopause in
women with normal cytology [14,15], a pattern not indicated in our
data, although it should be noted that our data included results from
all HPV-tested women as cytology was not part of the screening.
It has been hypothesized that HPV-prevalence and cervical cancer
incidence would increase due to the effect of increasing exposure to
HPV in the post-1945 cohorts [16]. In a United States survey from
2008 to 2011, 65% of women aged 35–39 reported to have had 5 or
more sexual partners in their lifetime, while this percentage was 55%
in women aged 55–60 [17]. Modelling of data from the United States
National Health and Nutrition Examination Survey indicated a substan-
tial increase in HPV prevalence in more recent birth cohorts [18]. When
our sampleswere collected in 2017,women born in 1945were 72 years
old, and the HPV-prevalence in women aged 69–73 did not differ from
the gradual decline with increasing age. Future data will showwhether
this pattern will change with the aging of upcoming generations.
One exception from the decreasing pattern in our datawas the HPV-
prevalence of 5.2% in women aged 89 and older, though based on very
small numbers. It might be noted, however, that these women were
born in the late 1920s and were young at the end of World War II,
where Denmark had a record high number of sexually transmitted dis-
eases [19].
Denmark is among the countries with a bipolar pattern in the age-
specific incidence of cervical cancer (Fig. 2); both in the observed
rates fromNORDCAN from 2011 to 2015 [20], and in the rates corrected
for number of hysterectomised women [12]. Our data did not support
the hypothesis that the second peak in the bipolar pattern of cervical
cancer incidence was related to an increase in active HPV-infection in
older age. An alternative pathway for cervical cancer in old age might
be reactivation of an existing HPV-infection, e.g. initiated by use of ste-
roids suggested to increase the risk of HPV-persistency [21].
It is an attractive idea that another screen at 75 or 80 years in those
who have not had 3 normal prior to 65 years might detect the interval
cancers from persistent HPV. It should be noted, however, that an HPV
infectionmay become undetectable at a late stage of the oncogenic pro-
cess [22]; an observation supported by our data where the old age peak
in cervical cancer incidence was not reflected in the HPV-prevalence
pattern. At present, Danish women exit the regular screening program
at age 60–64 with an HPV-test. The fact that 4% of women aged 69–73were HPV-positive in the present study indicates a need for monitoring
outcome of the exit-tests.
The further follow-up of the HPV-positive, elderly womenwill show
whether the second peak is reflected in the detection of pre-cancerous
lesions.
5. Conclusion
Invitation to HPV-screening was well received by elderly women
with in total 30% of women 69 year and above participating. The overall
HPV-prevalencewas 4.3%. In combinationwith data frompreviousDan-
ish studies, our data indicated a high HPV-prevalence up until the age of
35, where after a gradual decline of the HPV-prevalence was observed
with increasing age.
Supplementary data to this article can be found online at https://doi.
org/10.1016/j.ygyno.2019.04.680.
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